Nuvation Bio Inc.
Financials
Valuation Metrics
Nuvation Bio Inc.'s Market Cap is $1.66B. At end of 2025 it was $3.09B. Ranked #2121 of 3,116 in US market (top 68%), #1300 of 1,644 on NYSE (top 79%), #150 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.66B | US#2,121/3,116 Sec#150/265 |
| Net Income | $-150M | US—/3,116 Sec—/265 |
| Total Assets | $745M | US#2,594/3,116 Sec#125/265 |
| Net Assets | $254M | US#2,576/3,116 Sec#165/265 |
| Employees | 305 | US#2,404/3,116 Sec#108/265 |
| Value | ||
| P/B | 6.54x | US#2,388/3,116 Sec#164/265 |
| P/S | 33.74x | US#2,891/3,116 Sec#158/265 |
| FCF Yield | -4.98% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -59.02% | US#2,708/3,116 Sec#172/265 |
| ROA | -20.12% | US#2,789/3,116 Sec#130/265 |
| Financial Health | ||
| Debt Ratio | 193.27% | US#1,751/3,116 Sec#196/265 |
| Total Debt | $252M | US#2,158/3,116 Sec#89/265 |
| FCF | $-83M | US#2,602/3,116 Sec#133/265 |
| Cash | $259M | US#1,530/3,116 Sec#91/265 |
| Current Ratio | 8.37x | US#302/3,116 Sec#91/265 |
| Performance | ||
| 1Y Return | -7.38% | US#2,123/3,116 Sec#170/265 |
| 1M Return | -14.82% | US#2,762/3,116 Sec#220/265 |
| From 52W High | -51.08% | US#2,685/3,116 Sec#206/265 |
| 1Y MDD | -57.55% | US#2,673/3,116 Sec#197/265 |
| Trading | ||
| Volume | 4,072,632 shares | US#316/3,116 Sec#25/265 |
| Trading Value | $19M | US#1,696/3,116 Sec#126/265 |
| Per Share | ||
| EPS | $-0.43 | US—/3,116 Sec—/265 |
| BPS | $0.73 | US#2,721/3,116 Sec#208/265 |
Company Info
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.